Ganga Pharmaceuticals Limited has announced the implementation of a special window facility to assist shareholders with the transfer and dematerialisation of physical securities. The initiative represents a significant opportunity for shareholders holding physical share certificates to convert them to electronic format under regulatory guidelines.

SEBI Circular Implementation

The special window has been established pursuant to SEBI Circular No. HO/3813/11/2/2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The facility will remain operational for a period of one year, commencing from February 05, 2026 and concluding on February 04, 2027.

Eligible Cases

The special window facility will be applicable in specific scenarios related to physical securities transactions. The company has outlined two primary categories of eligible cases for shareholders to utilize this facility.

Eligible shareholders include those where original share transfer requests were not lodged prior to April 01, 2019, and the shareholder continues to hold the original share certificate. Additionally, the facility covers cases where original share transfer requests were lodged prior to April 01, 2019, but were subsequently rejected, returned, or not attended due to deficiencies in documents, processes, or other issues, with the shareholder still holding the original share certificate.

Processing Requirements

Shareholders seeking to utilize this facility must furnish necessary documents to the company's designated Registrar and Share Transfer Agent. KFin Technologies Limited has been appointed to handle the processing of these requests.

Transfer Conditions

The company has specified important conditions that will apply to shares processed through this special window. All shares will be mandatorily credited to the transferee only in demat mode, ensuring electronic holding of the securities.

A significant restriction applies to the transferred shares, which will be subject to a lock-in period of one year from the date of registration of transfer. During this lock-in period, the securities cannot be transferred, lien marked, or pledged, providing regulatory protection for the transfer process.

Company Communication

The announcement was made through newspaper publications in "Financial Express" (English) and "Mumbai Lakshdeep" (Marathi) on March 14, 2026. The information has also been made available on the company's website at www.ayurvedganga.com for shareholder reference and accessibility.

Ganga Pharmaceuticals Limited has announced the re-appointment of its Managing Director following a board meeting held on March 10, 2026. The pharmaceutical company's board approved the extension of Mr. Bharat Brijmohan Sharma's tenure for another three-year term, demonstrating confidence in his leadership capabilities.

Board Decision and Regulatory Compliance

The Board of Directors approved the re-appointment based on recommendations from both the Nomination and Remuneration Committee and the Audit Committee. The decision was made during a board meeting that commenced at 4:00 p.m. and concluded at 4:30 p.m. on March 10, 2026. The company has filed the necessary intimation pursuant to Regulation 30 of the SEBI Listing Regulations.

Leadership Profile and Experience

Mr. Bharat Brijmohan Sharma brings substantial industry expertise to his continued role as Managing Director. According to the company's disclosure, he possesses over 35 years of experience in Business and Pharma Industry, providing valuable leadership for the pharmaceutical company's operations.

Corporate Governance and Compliance

The company has confirmed that Mr. Sharma is not debarred from holding the office of Director by virtue of any SEBI order or order of any other authority. This compliance disclosure ensures adherence to regulatory requirements for director appointments and maintains transparency with stakeholders.

Family Connections and Board Structure

The disclosure reveals family connections within the company's leadership structure. Mrs. Srijna Sharma, who serves as a Whole-time Director of the Company, is the spouse of Mr. Bharat Brijmohan Sharma. This relationship has been transparently disclosed as part of the regulatory requirements.

Next Steps and Shareholder Approval

While the Board of Directors has approved the re-appointment, the decision remains subject to approval from the company's members. The re-appointment will take effect from April 01, 2026, marking the beginning of Mr. Sharma's extended three-year tenure as Managing Director of Ganga Pharmaceuticals Limited. The information has been made available on the company's website at www.ayurvedganga.com .